{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T01:07:57Z","timestamp":1696900077693},"reference-count":24,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Chemotherapy"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1179\/joc.2010.22.1.54","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T13:06:12Z","timestamp":1389272772000},"page":"54-57","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Modified Rituximab-ESHAP Therapy for Relapsed\/Refractory B-Cell Lymphoma"],"prefix":"10.1080","volume":"22","author":[{"given":"K.","family":"Ueda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hangaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"issue":"4","key":"CIT0001","first-page":"235","volume":"346","author":"Coiffier B","year":"2002","journal-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in eld-erly patients with diffuse large-B-cell lymphoma. N Engl J Med"},{"issue":"12","key":"CIT0002","first-page":"1421","volume":"24","author":"Lin TY","year":"2005","journal-title":"[Com-parison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China\u2014a multi-center randomized trail]. Ai Zheng"},{"issue":"22","key":"CIT0003","first-page":"5027","volume":"23","author":"Sehn LH","year":"2005","journal-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.11.013"},{"issue":"23","key":"CIT0005","first-page":"1540","volume":"333","author":"Philip T","year":"1995","journal-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lym-phoma. N Engl J Med"},{"issue":"21","key":"CIT0006","first-page":"3918","volume":"21","author":"Schouten HC","year":"2003","journal-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.019"},{"issue":"12","key":"CIT0009","first-page":"1829","volume":"93","author":"Martin A","year":"2008","journal-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study. Haematologica"},{"issue":"11","key":"CIT0010","first-page":"1748","volume":"7","author":"Calvert AH","year":"1989","journal-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol"},{"key":"CIT0011","unstructured":"DeVita Ca. Cancer chemotherapy Drug Manual. 2002."},{"issue":"4","key":"CIT0012","first-page":"1244","volume":"17","author":"Cheson BD","year":"1999","journal-title":"Report of an international workshop to standardize response cri-teria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol"},{"issue":"7","key":"CIT0013","first-page":"1734","volume":"13","author":"Rodriguez MA","year":"1995","journal-title":"Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol"},{"issue":"3","key":"CIT0014","first-page":"159","volume":"21","author":"Park SH","year":"2006","journal-title":"ESHAP sal-vage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience. Korean J Intern Med"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1007\/BF00694330"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050578"},{"issue":"1","key":"CIT0017","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","volume":"17","author":"Go RS","year":"1999","journal-title":"J Clin Oncol"},{"issue":"14","key":"CIT0018","first-page":"987","volume":"329","author":"Project TIN-","year":"1993","journal-title":"The International Non-Hodgkin's Lymphoma Prognostic factors Project. N Engl J Med"},{"issue":"10","key":"CIT0019","first-page":"1015","volume":"7","author":"Bokemeyer C","year":"1996","journal-title":"A randomized trial of cisplatin, etoposide and bleomycin (PEB) ver-sus carboplatin, etoposide and bleomycin (CEB) for patients with \u2018good-risk\u2019 metastatic non-seminomatous germ cell tumors. Ann Oncol"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01384.x"},{"issue":"10","key":"CIT0021","first-page":"1629","volume":"34","author":"Imataki O","year":"2007","journal-title":"Gan To Kagaku Ryoho"},{"issue":"4","key":"CIT0022","first-page":"401","volume":"26","author":"Abali H","year":"2008","journal-title":"Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cy-tosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in Patients with relapsed or refractory lymphoma. Cancer Invest"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733030-00002"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199513040-00003"},{"issue":"6","key":"CIT0025","first-page":"1074","volume":"49","author":"Witzig TE","year":"2008","journal-title":"Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma"}],"container-title":["Journal of Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10256018808623883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T01:42:25Z","timestamp":1498095745000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1179\/joc.2010.22.1.54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,7,18]]},"published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1179\/joc.2010.22.1.54"],"URL":"https:\/\/doi.org\/10.1179\/joc.2010.22.1.54","relation":{},"ISSN":["1120-009X","1973-9478"],"issn-type":[{"value":"1120-009X","type":"print"},{"value":"1973-9478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}